Spero Therapeutics, Inc. (SPRO) — SEC Filings
Spero Therapeutics, Inc. (SPRO) — 31 SEC filings. Latest: 8-K (Dec 19, 2025). Includes 21 8-K, 6 10-Q, 2 10-K.
View Spero Therapeutics, Inc. on SEC EDGAR
Overview
Spero Therapeutics, Inc. (SPRO) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 19, 2025: On December 19, 2025, Spero Therapeutics, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific material events or transactions detailed in the provided text.
Sentiment Summary
Across 31 filings, the sentiment breakdown is: 2 bullish, 2 bearish, 26 neutral, 1 mixed. The dominant filing sentiment for Spero Therapeutics, Inc. is neutral.
Filing Type Overview
Spero Therapeutics, Inc. (SPRO) has filed 21 8-K, 6 10-Q, 2 10-K, 1 DEF 14A, 1 SC 13G with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (31)
Risk Profile
Risk Assessment: Of SPRO's 26 recent filings, 3 were flagged as high-risk, 10 as medium-risk, and 13 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $5.44M |
| Net Income | -$7.38M |
| EPS | -$0.13 |
| Debt-to-Equity | N/A |
| Cash Position | $48.62M |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- David E. Melnick
- Jonathan J. Lim
Industry Context
Spero Therapeutics operates in the highly competitive and capital-intensive biotechnology sector, specifically focusing on novel anti-infectives. The industry faces challenges related to antibiotic resistance, lengthy and expensive drug development cycles, and stringent regulatory hurdles. Companies like Spero often rely on strategic partnerships and significant R&D investment to bring new therapies to market.
Top Tags
corporate-governance (6) · financial-reporting (5) · financial-condition (4) · 10-Q (4) · 8-K (3) · Pharmaceuticals (3) · operations (3) · Spero Therapeutics (3) · SEC Filing (2) · Financials (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Commission File Number | 001-38266 | Identifies Spero Therapeutics' SEC filings. |
| IRS Employer Identification No. | 46-4590683 | Tax identification for Spero Therapeutics. |
| Net Loss (Q3 2025) | $7.38M | Reduced from $17.15M in Q3 2024, indicating improved financial performance. |
| Net Loss (9 Months 2025) | $22.95M | Reduced from $47.68M in 9 months 2024, showing a significant decrease in losses. |
| Total Revenues (Q3 2025) | $5.44M | Decreased from $13.47M in Q3 2024, primarily due to lower grant and collaboration revenue. |
| R&D Expenses (9 Months 2025) | $32.88M | Substantially reduced from $67.92M in 9 months 2024, reflecting strategic reprioritization. |
| Cash and Cash Equivalents (Sept 30, 2025) | $48.62M | Decreased from $52.89M at Dec 31, 2024, indicating ongoing cash burn. |
| Common Stock Shares Outstanding | 56,339,295 | As of November 6, 2025, indicating dilution from 54,593,527 shares at Dec 31, 2024. |
| Net Loss Per Share (Q3 2025) | $0.13 | Improved from $0.32 in Q3 2024. |
| Net Loss Per Share (9 Months 2025) | $0.41 | Improved from $0.89 in 9 months 2024. |
| Net Loss | $19.9M | Increased from $10.1M in Q2 2024, indicating higher cash burn. |
| Revenue | $1.1M | Decreased from $1.3M in Q2 2024, primarily due to lower collaboration revenue. |
| R&D Expenses | $10.1M | Decreased by $1.9M from Q2 2024, mainly due to reduced SPR720 clinical costs. |
| G&A Expenses | $10.9M | Increased by $1.2M from Q2 2024, driven by higher personnel costs. |
| Cash & Equivalents | $70.1M | Decreased from $90.2M at Dec 31, 2024, highlighting liquidity concerns. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Spero Therapeutics, Inc. (SPRO)?
Spero Therapeutics, Inc. has 31 recent SEC filings from Jan 2024 to Dec 2025, including 21 8-K, 6 10-Q, 2 10-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of SPRO filings?
Across 31 filings, the sentiment breakdown is: 2 bullish, 2 bearish, 26 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Spero Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Spero Therapeutics, Inc. (SPRO) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Spero Therapeutics, Inc.?
Key financial highlights from Spero Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for SPRO?
The investment thesis for SPRO includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Spero Therapeutics, Inc.?
Key executives identified across Spero Therapeutics, Inc.'s filings include David E. Melnick, Jonathan J. Lim.
What are the main risk factors for Spero Therapeutics, Inc. stock?
Of SPRO's 26 assessed filings, 3 were flagged high-risk, 10 medium-risk, and 13 low-risk.
What are recent predictions and forward guidance from Spero Therapeutics, Inc.?
Forward guidance and predictions for Spero Therapeutics, Inc. are extracted from SEC filings as they are enriched.